Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Monday, June 13, 2025
Supernus’s $795 Million Acquisition of Sage
Klotho’s $11 Million Warrant Exercise
Thursday, June 12, 2025
Insmed’s $750 Million Public Offering
ADC’s $100 Million Private Placement
Quince’s $22 Million Private Placement
Parallel’s $21 Million Series A
Mezzion’s $20 Million Fund Raise
Enterome’s $19 Million Private Placement
Intensity’s $2 Million Public Offering
PreveCeutical’s $750 Thousand Private Placement
Wednesday, June 11, 2025
Cogent’s $400 Million Debt Financing
SpliceBio’s $135 Million Series B
Pharmazz’s $25 Million Equity Investment
Tempest’s $5 Million Registered Direct Offering
Tuesday, June 10, 2025
Antares’s $177 Million Series A
Citius’ $16 Million Registered Direct Offering
32 Biosciences’ $6 Million Series A
Monday, June 9, 2025
Mosanna’s $80 Million Series A
Concentra’s $26 Million Acquisition of Elevation
ReShape’s $3 Million Public Offering
Friday, June 6, 2025
Aytu’s $14 Million Public Offering
Rakovina’s $5 Million Private Placement
Thursday, June 5, 2025
Kelun’s $250 Million Fund Raise
QureBio’s $14 Million Series C1
Cellectar’s $2 Million Warrants Exercise
GlycoMimetics’s Merger with Crescent
Wednesday, June 4, 2025
Leyden’s $23 Million Debt Financing
Elicio’s $10 Million Venture Financing
Alvotech’s $10 Million Private Placement
Tuesday, June 3, 2025
SpyGlass’s $75 Million Series D
Antheia’s $56 Million Series C
TuHURA’s $12 Million Equity Investment and $3 Million Warrant Exercise
Estrella’s $3 Million Private Placement
Monday, June 2, 2025
Sanofi’s $9.1 Billion Acquisition of Blueprint…More
Merus’s $300 Million Public Offering
Theravance’s $225 Million Royalty Financing
Trevi’s $100 Million Public Offering
SpyGlass’s $75 Million Series D
Sponsors
In coordination with an executive placement firm that is independent and unaffiliated with Collabrity, Inc., we may coordinate with executive(s) who are sourced by that firm and also independent and unaffiliated with Collabrity, Inc.: “Collabrity Executive(s)” does not imply an employment or independent contractor relationship with Collabrity, Inc.
Securities offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity Inc. is not a registered broker-dealer, and Finalis Securities LLC and Collabrity Inc. are separate, unaffiliated entities. Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck